AKBA · Company research
Akebia Therapeutics, Inc. (AKBA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| The commercial chief at Akebia Therapeutics (AKBA) plans to resign for personal reasons. - Stock Titan | The commercial chief at Akebia Therapeutics (AKBA) plans to resign for personal reasons. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Commercial products and rare kidney disease drug candidates are on Akebia's agenda at online meetings. - Stock Titan | Commercial products and rare kidney disease drug candidates are on Akebia's agenda at online meetings. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Has Average Target Price of $3.90 - MarketBeat | Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Has Average Target Price of $3.90 MarketBeat | View source ↗ | MarketBeat | Oct 7, 2026 | neutral | 0 | 0.6 |
| Akebia Therapeutics, Inc. (AKBA) Stock Price, News, Quote & History - Yahoo! Finance Canada | Akebia Therapeutics, Inc. (AKBA) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 7, 2026 | neutral | 0 | 0.6 |
| Akebia Therapeutics (AKBA) Slips 3.28% to $0.88 as Shares Test Key Support - Dark Pool Sentiment - https://www.siam.in/ | Akebia Therapeutics (AKBA) Slips 3.28% to $0.88 as Shares Test Key Support - Dark Pool Sentiment https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 6, 2026 | neutral | 0 | 0.6 |
| A study will present safety results on a three-times-weekly anemia drug for people getting in-center dialysis - Stock Titan | A study will present safety results on a three-times-weekly anemia drug for people getting in-center dialysis Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| A new hire's right to buy 8,400 Akebia shares phases in over four years, if they stay. - Stock Titan | A new hire's right to buy 8,400 Akebia shares phases in over four years, if they stay. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Akebia Therapeutics (NasdaqCM:AKBA) Stock Forecast & Analyst Predictions - Simply Wall Street | Akebia Therapeutics (NasdaqCM:AKBA) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 14, 2026 | neutral | 0 | 0.6 |
| Akebia Therapeutics (AKBA) Stock Price Sinks As Losses Deepen Value Doubts - Simply Wall Street | Akebia Therapeutics (AKBA) Stock Price Sinks As Losses Deepen Value Doubts Simply Wall Street | View source ↗ | Simply Wall Street | Aug 7, 2026 | neutral | 0 | 0.6 |
| $AKBA stock is down 28% today. Here's what we see in our data. - Quiver Quantitative | $AKBA stock is down 28% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 6, 2026 | neutral | 0 | 0.6 |
| Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance | Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 5, 2026 | neutral | 0 | 0.6 |
| AKBA Looks 1.2% Overvalued on GF Value™ as Market Prices in Mode - GuruFocus | AKBA Looks 1.2% Overvalued on GF Value™ as Market Prices in Mode GuruFocus | View source ↗ | GuruFocus | Aug 5, 2026 | neutral | 0 | 0.6 |
| Akebia: Vafseo Gains Traction, But It’s Still A Show-Me Story (Rating Downgrade) (AKBA) - Seeking Alpha | Akebia: Vafseo Gains Traction, But It’s Still A Show-Me Story (Rating Downgrade) (AKBA) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 14, 2026 | neutral | 0 | 0.6 |
| Akebia Therapeutics(AKBA) Stock Options Chain | Quotes & News - Moomoo | Akebia Therapeutics(AKBA) Stock Options Chain | Quotes & News Moomoo | View source ↗ | Moomoo | Jul 13, 2026 | neutral | 0 | 0.6 |
| $AKBA stock is down 13% today. Here's what we see in our data. - Quiver Quantitative | $AKBA stock is down 13% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | May 19, 2026 | neutral | 0 | 0.6 |
| Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy - Yahoo Finance | Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy Yahoo Finance | View source ↗ | Yahoo Finance | Mar 31, 2026 | neutral | 0 | 0.6 |
| AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits | AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction Stocktwits | View source ↗ | Stocktwits | Mar 5, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.